Why we invested in Fleetzero The global economy runs on ocean freight. Ninety percent of goods travel by sea at some point in their journey. The dirty secret, though, is that shipping accounts for roughly 2.5% of global greenhouse gas emissions, produces over half of the smog in Los Angeles…

Why we invested in Character Biosciences Given what we know about the diversity and heterogeneity locked within biology, it’s surprising that most drugs are still discovered and prescribed as one-size-fits-all. The typical process involves identifying a gene or target, modifying drug chemistry to block (or activate) that target, and running…

Why we invested in Mako Aerospace — Today, aviation contributes 3–4% of total greenhouse gas emissions, and it’s estimated to increase substantially. Electrification has become the popular choice for decarbonizing modes of transportation. Climate change is undoubtedly a contributor to the urgency, but there are economic benefits to electrification as well. Not only is electricity cheaper than…

Why we invested in Radiant — The Status Quo We have just begun to feel the devastation of climate change. Unless global greenhouse emissions fall by 7.6% per year between 2020 and 2030, things will only get worse. Even with the pandemic-induced reduction in traffic, carbon emissions fell by only 6%. …

Why we invested in Faeth Therapeutics Have you ever heard stories of someone convinced they or a loved one cured cancer with a juice cleanse or fad diet? …

Why we invested in Atomos Space — The Status Quo Imagine flying, but you had to walk from the airport to your destination when you landed. That’s the current reality for satellites. Launch vehicles, which run at a bargain cost of ~$62 million thanks to SpaceX, cater to specific orbits — primarily a function of their size and launch site…

Where Frontier Tech is Headed in 2022 — In many ways, 2021 was the year of deep tech. We started the year with a biotech breakthrough — mRNA vaccines that were approved in record time to bring us on course towards a return to pre-pandemic life. We saw a boom in space exploration and a renewed urgency for…

Why we invested in Sixfold Bioscience We’ve all seen — experienced even — the power of RNA this year. It took one vaccine and a global pandemic to promote RNA from a niche area of life science to a household name. …

Why we invested in Nabla Bio Getting even one drug from the research lab to the clinic is a multi-step process that takes an average of $2.6B and 12 years — that is if the drug has not failed before reaching full approval, a milestone less than 0.02% of potential…